Researchers have determined that intravenous sodium bicarbonate treatment has no effect on mortality in critically ill patients with severe acidemia and moderate to severe acute kidney injury (AKI). The treatment can, however, decrease the use of kidney replacement therapy (KRT). The results are from the BICARICU-2 randomized trial, which took place at 43 intensive care units (ICUs) in France. In contrast to the absence of mortality advantage, the treatment had a 41% reduced risk of KRT onset, indicating the potential for early dialysis prevention in carefully selected patients. The study was published in JAMA by Boris J. and colleagues.

The BICARICU-2 trial, run by Dr. Boris Jung and others at Lapeyronie University Hospital, Montpellier, was an open-label, multicenter, randomized contr

See Full Page